UK Markets close in 29 mins
  • FTSE 100

    6,555.36
    +65.09 (+1.00%)
     
  • FTSE 250

    20,150.10
    +17.66 (+0.09%)
     
  • AIM

    1,067.74
    +1.53 (+0.14%)
     
  • GBP/EUR

    1.1097
    +0.0024 (+0.21%)
     
  • GBP/USD

    1.3474
    +0.0021 (+0.1563%)
     
  • BTC-GBP

    14,089.28
    -226.50 (-1.58%)
     
  • CMC Crypto 200

    372.37
    -6.88 (-1.81%)
     
  • S&P 500

    3,692.46
    +25.74 (+0.70%)
     
  • DOW

    30,150.79
    +181.27 (+0.60%)
     
  • CRUDE OIL

    45.99
    +0.35 (+0.77%)
     
  • GOLD FUTURES

    1,836.20
    -4.90 (-0.27%)
     
  • NIKKEI 225

    26,751.24
    -58.13 (-0.22%)
     
  • HANG SENG

    26,835.92
    +107.42 (+0.40%)
     
  • DAX

    13,275.62
    +22.76 (+0.17%)
     
  • CAC 40

    5,600.48
    +26.12 (+0.47%)
     

Arix to Present at the Jefferies Virtual London Healthcare Conference

·2-min read

Arix Bioscience PLC (ARIX)
12-Nov-2020 / 07:00 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

Arix Bioscience plc

 

Arix to Present at the Jefferies Virtual London Healthcare Conference

 

LONDON, 12 November 2020: Arix Bioscience plc ("Arix", LSE: ARIX), a global venture capital company focused on investing and building breakthrough biotech companies, today announces that Dr. Naseem Amin, Executive Chairman, is scheduled to participate in an analyst led fireside chat at the Jefferies Virtual London Healthcare Conference on Tuesday, 17 November 2020, at 10:35am GMT.

 

A live webcast of the fireside chat will be available on the investor relations section of Arix's website at https://arixbioscience.com/investor-relations/events-presentations. After the conference, an archived replay will be available on the company's website at the same address.

 

[ENDS]

 

Enquiries

For more information on Arix, please contact:

 

Arix Bioscience plc

Charlotte Parry, Head of Investor Relations

+44 (0)20 7290 1072

charlotte@arixbioscience.com

 

Optimum Strategic Communications

Supriya Mathur, Shabnam Bashir, Manel Mateus

+44 (0)20 3922 1906

optimum.arix@optimumcomms.com

 

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.

 

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.

 

For more information please visit: www.arixbioscience.com


ISIN:

GB00BD045071

Category Code:

MSCM

TIDM:

ARIX

LEI Code:

213800OVT3AHQCXNIX43

OAM Categories:

3.1. Additional regulated information required to be disclosed under the laws of a Member State

Sequence No.:

87702

EQS News ID:

1147540


 

End of Announcement

EQS News Service

show this
show this